Bolt Projects Holdings, Inc.

Bolt Projects Holdings, Inc. is a U.S.-based specialty materials company built around its Vegan Silk Technology Platform, which it uses to develop and sell biomaterial products for beauty and personal care applications. The company’s current commercial focus is b-silk, a product positioned as a substitute for silicone elastomers in formulations. Bolt also previously worked on Mylo, a mycelium-based leather alternative, but discontinued that program in early 2023 to concentrate on Vegan Silk commercialization. Following a 2024 reverse merger, the operating business of Bolt Threads became the business of Bolt Projects Holdings, Inc., and the company now trades on Nasdaq under the ticker BSLK.

−3 030,3 %

−6,8 %

−4 762,8 %

−60,1 %

1.28

1.02

— Bolt Projects Holdings, Inc.
%
Commercial biomaterial products90% Finished products sold to customers, primarily b-silk derived from the Vegan Silk Technology Platform.
Technology platform development5% Internal R&D and product development work to extend the Vegan Silk platform into new applications.
Manufacturing and supply chain services5% Production, warehousing, packaging, and shipping activities supporting product delivery.

Bolt sells primarily into the beauty and personal care market, where formulators use b-silk as an ingredient substitute...

  • Beauty and personal care formulatorsprimary

    They buy b-silk to improve texture, feel, and formulation performance while replacing silicone elastomers.

  • Cosmetics and personal care brandsprimary

    They use Bolt’s materials through finished formulations to support product differentiation and vegan/clean-label positioning.

  • Ingredient distributors and commercial partnerssecondary

    They help place the product into formulations and broaden market access for the Vegan Silk platform.

  • Potential adjacent biomaterial customersemerging

    They may adopt future products from the platform if Bolt expands beyond b-silk into new applications.

The available filings do not disclose a country-by-country revenue split, so Bolt’s geographic profile must be inferred...

  • •United States headquarters and Nasdaq listing create U.S. capital-market exposure
  • •No country-level revenue disclosure was provided in the excerpts
  • •Manufacturing depends on a single partner, Laurus Bio
  • •Operational footprint is asset-light rather than owned-factory based
  • •Geography matters mainly through supply-chain continuity and listing compliance

Bolt’s strategy is to focus resources on the Vegan Silk Technology Platform and commercialize b-silk rather than spread...

01
Commercialize b-silkshort-term

It is the company’s principal revenue source and the clearest path to scaling sales.

02
Focus R&D on the Vegan Silk platformmedium-term

Platform innovation is needed to maintain differentiation and create follow-on products.

03
Secure manufacturing capacity and supply reliabilityshort-term

The company relies on a single manufacturing partner, so continuity of supply is critical.

04
Strengthen capital structure and public-company executionshort-term

The business is growth-stage and may need external financing while managing Nasdaq requirements.

Bolt’s biggest company-specific risk is concentration: substantially all revenue currently comes from b-silk, so any...

high

Product concentration in b-silk

Substantially all revenue is derived from one product platform, so demand weakness would directly hit sales.

Scope
Revenue and growth
Materiality
high
high

Single manufacturing partner dependency

The company relies on Laurus Bio to produce Vegan Silk products, so any disruption could impair supply.

Scope
Operations and fulfillment
Materiality
high
high

Nasdaq delisting or continued listing non-compliance

The company received Nasdaq notices regarding market value and equity standards, which can affect liquidity and capital access.

Scope
Capital markets
Materiality
high
medium

Customer adoption uncertainty

The company says awareness and experience with its products are limited, making demand hard to predict.

Scope
Commercialization
Materiality
high
medium

Funding and dilution risk

Growth-stage operations and expansion plans may require additional equity or debt financing.

Scope
Balance sheet and ownership dilution
Materiality
high
Revenue recognition on shipment
Quarterly revenue volatility and cut-off risk
Inventory impairment and manufacturing costs
Gross loss and margin volatility
Stock-based compensation
Operating expense burden and diluted earnings
Reverse merger accounting
Period-to-period comparability

Bolt Biotherapeutics, Inc.

BOLT · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

KULR Technology Group, Inc.

KULR · Electronic Components & Accessories

Charlie's Holdings, Inc.

CHUC · Medicinal Chemicals & Botanical Products

Abpro Holdings, Inc.

ABPO · Biological Products, (No Diagnostic Substances)

Krystal Biotech, Inc.

KRYS · Biological Products, (No Diagnostic Substances)

: 11/08/2026